How Does Spironolactone Affect Hormones?

Spironolactone affects hormones along at least three distinct pathways: it blocks the action of aldosterone in the kidneys, competes with androgens like testosterone and dihydrotestosterone at their receptors throughout the body, and nudges cortisol levels upward by interfering with the brain’s feedback system for stress hormones. Originally developed as a blood-pressure drug, its hormonal side effects turned out to be so useful that spironolactone is now prescribed off-label for acne, excessive hair growth, polycystic ovary syndrome, and as part of gender-affirming hormone therapy. The breadth of its hormonal reach also explains why it causes side effects that most blood-pressure medications never would.

Blocking Aldosterone in the Kidneys

Spironolactone’s original and still most common medical purpose is to counteract aldosterone, a hormone your adrenal glands release to tell your kidneys to hold on to sodium and water. In conditions like heart failure, liver cirrhosis, and a disorder called primary hyperaldosteronism, the body produces too much aldosterone, leading to fluid retention and dangerously high blood pressure. Spironolactone works by physically sitting in the same receptor that aldosterone normally binds to, preventing aldosterone from delivering its “retain salt and water” message.¹ The result is that your kidneys release more sodium and water, lowering blood pressure and reducing swelling.

This aldosterone-blocking action is what classifies spironolactone as a “potassium-sparing diuretic.” Most diuretics cause you to lose potassium along with water, but because aldosterone also controls potassium excretion, blocking it means potassium stays in your bloodstream. That is a benefit for people who are potassium-depleted, but it creates a real risk of dangerously high potassium levels, which is why regular blood tests are standard for anyone taking the drug.

How It Interferes With Androgens

The hormonal effect that gets the most attention outside cardiology is spironolactone’s ability to block androgens, the group of hormones that includes testosterone and its more potent derivative, dihydrotestosterone (DHT). Spironolactone physically competes with DHT for binding to androgen receptors, the proteins on cells that respond to male sex hormones. In laboratory experiments, spironolactone was found to be roughly twenty times less potent than DHT at occupying the receptor, which sounds weak but is enough to matter at the doses used clinically.² The drug also inhibits certain enzymes involved in making androgens in the first place, so it hits the androgen system from two directions: less androgen produced and less androgen able to do its job at the cellular level.³

This dual mechanism is why spironolactone is effective for skin and hair conditions driven by androgen activity. Androgens stimulate oil glands in the skin and trigger the growth of coarse, dark hair in hormone-sensitive areas. By dulling the androgen signal at those tissues, spironolactone reduces oiliness and slows unwanted hair growth even when actual testosterone levels in the blood do not change dramatically.

What Happens to Circulating Hormone Levels

A common expectation is that an “anti-androgen” drug must lower testosterone levels in the blood. In practice, the picture is more nuanced. Several studies in women with excess androgen activity have found that total testosterone and other androgen markers like androstenedione and DHEA-S do not drop significantly after months of spironolactone use.⁴ One study comparing spironolactone to another anti-androgen, cyproterone acetate, found that cyproterone reduced testosterone levels by nearly half in women with polycystic ovary syndrome, while spironolactone left testosterone essentially unchanged.⁴

What does shift is how testosterone distributes itself in the blood. In one trial, after three months of spironolactone, the portion of testosterone bound to sex-hormone-binding globulin (SHBG) went down, while the “free” and albumin-bound fractions went up.⁵ That is a somewhat counterintuitive result: the drug is anti-androgenic in its clinical effects, yet the freely available testosterone in the blood actually increased. The explanation is that spironolactone’s main anti-androgen work happens at the receptor level, not by clearing testosterone from the bloodstream. It blocks the lock, not the key.

Separately, some data suggest spironolactone causes a modest tendency for SHBG levels to rise, though this effect has not consistently reached statistical significance.⁶ Other anti-androgen studies that combined spironolactone with additional treatments have reported significant drops in both total and free testosterone, but it is difficult to tease apart spironolactone’s solo contribution in those cases.⁷

Effects on Cortisol and the Stress Hormone System

Less well known is spironolactone’s influence on cortisol, the body’s primary stress hormone. The mineralocorticoid receptors that spironolactone blocks in the kidneys also exist in the brain, where they play a role in regulating the hypothalamic-pituitary-adrenal (HPA) axis, the feedback loop that controls cortisol release. When spironolactone blocks those brain-based receptors, the brain interprets it as if mineralocorticoid levels are low and ramps up the stress-hormone cascade.

Research in healthy volunteers showed that even a single dose of spironolactone caused a significant rise in plasma cortisol, preceded by increases in ACTH, the pituitary hormone that signals the adrenal glands to produce cortisol. After two doses, cortisol stayed elevated for the entire monitoring period.⁸ A separate study confirmed the effect using a standard stress-hormone challenge test: people taking spironolactone had roughly double the cortisol response compared to placebo.⁹

In people with chronic heart failure, spironolactone use was associated with a significant rise in cortisol, climbing from about 11 to nearly 15 micrograms per deciliter on average. That cortisol increase correlated with a small but significant uptick in HbA1c, a marker of blood sugar control, which makes sense given that cortisol raises blood glucose.¹⁰ For most healthy people taking spironolactone for skin or hair conditions, this cortisol bump is unlikely to cause noticeable problems. But for people with diabetes, pre-diabetes, or conditions where cortisol management matters, it is worth knowing about.

Uses Driven by Hormonal Effects

Spironolactone’s anti-androgen properties have made it a workhorse for conditions where androgen activity causes visible symptoms, particularly in women.

For acne, androgens are the main driver of excess sebum, the oily substance that clogs pores. Because spironolactone blocks androgen receptors and has been shown to reduce sebum production, it has become a widely accepted non-antibiotic option for women whose acne is hormonally driven.¹¹ It is generally not prescribed to men for acne because the anti-androgen effects at typical doses would cause feminizing side effects like breast tenderness and growth.

For hirsutism, the growth of coarse, dark hair in typically male-pattern areas like the chin and chest, spironolactone remains a first-line medical option for women. Clinical improvements tend to be gradual, often taking six months or longer to become obvious, because hair growth cycles are slow. Studies comparing spironolactone to cyproterone acetate found that while both reduce hirsutism scores, cyproterone performed somewhat better in women with PCOS, partly because it also directly suppresses testosterone production through a different mechanism.⁴

In PCOS more broadly, spironolactone is often used alongside other treatments to manage androgen-driven symptoms. Anti-androgen therapy in PCOS patients has been associated with reductions in hirsutism scores and improvements in quality of life, with some studies reporting significant drops in both total and free testosterone when spironolactone is part of a treatment plan.⁷

Role in Gender-Affirming Hormone Therapy

In feminizing hormone therapy for transgender women, spironolactone is one of the most commonly used anti-androgens in the United States, typically prescribed alongside estradiol. Its job in this context is to suppress the effects of testosterone, complementing the estrogen’s feminizing effects. A clinic-based study of transgender women found that with medical treatment, median testosterone levels fell from about 385 nanograms per deciliter at the first visit to consistently under 130 ng/dL by twelve months, with the most responsive patients reaching levels as low as 27 ng/dL.¹² Because these patients are taking estradiol simultaneously, the testosterone suppression reflects combined therapy rather than spironolactone alone.

There is ongoing discussion about whether spironolactone is the best anti-androgen option for this purpose. Alternatives like cyproterone acetate and GnRH analogues suppress testosterone through different mechanisms, and each comes with its own trade-offs. Cyproterone is not available in the United States due to regulatory concerns, while GnRH analogues are expensive, which helps explain spironolactone’s popularity in American clinics despite its less targeted hormonal profile.¹³

Why Men Experience Different Side Effects

In men, spironolactone’s anti-androgen effects are less a feature and more a liability. Breast tenderness, breast tissue growth (gynecomastia), and sexual dysfunction are well-documented problems when men take spironolactone for heart failure or blood pressure. A large retrospective study of patients with primary aldosteronism found that side effects were significantly more common in men taking doses above 50 milligrams daily compared to 50 mg or below, with about 39% of higher-dose patients experiencing adverse effects versus 29% of lower-dose patients.¹⁴ The difference was statistically significant only in men, underscoring that the anti-androgen effects are dose-related and hit men harder.

Pharmacovigilance analyses comparing spironolactone to newer mineralocorticoid receptor blockers like eplerenone and finerenone confirm the pattern. Spironolactone was uniquely associated with reproductive and endocrine adverse events, including extremely rare reports of conditions like male endometriosis. Neither eplerenone nor finerenone showed similar sex-hormone-related signals, because they were designed to be more selective for the mineralocorticoid receptor and largely avoid the androgen receptor altogether.¹⁵ Spironolactone also showed disproportionately higher reporting of reproductive, endocrine, psychiatric, and skin-related adverse events compared to finerenone in a separate analysis of FDA adverse event data.¹⁶

What Happens When You Stop

Spironolactone itself clears the body relatively quickly. Its main active metabolite, canrenone, has an elimination half-life of about 23 hours, with the broader pool of metabolites taking roughly 29 hours to halve.¹⁷ That means the drug is mostly out of your system within a few days of your last dose. But its clinical effects can persist far longer than the drug’s physical presence would suggest.

A study of women who took spironolactone for androgen-related skin and hair conditions found that about two-thirds of patients still experienced benefits an average of nearly 34 months after stopping the medication. The remaining third relapsed about 17 and a half months after discontinuation.¹⁸ Why the effects lingered so long after the drug was gone is not entirely clear, but it suggests spironolactone may nudge the hormonal environment in ways that take time to revert, or that for some patients the underlying hormonal imbalance naturally improves during the years of treatment. Women with the ovulatory form of PCOS tended to relapse earlier than those with the classic form, hinting that the underlying hormonal disorder’s severity matters for how durable the benefit is.¹⁸

Pregnancy Risk and Fetal Hormones

Spironolactone is classified as a pregnancy risk because its anti-androgen effects can interfere with the normal hormonal development of a male fetus. Androgens are essential for the formation of male genitalia during pregnancy, and by competing with dihydrotestosterone at androgen receptors and inhibiting enzymes in the androgen synthesis pathway, spironolactone creates a theoretical risk of feminizing a male fetus.³ The exact mechanisms behind how this could affect genital development have not been fully worked out in humans, but animal studies have demonstrated the effect clearly enough that spironolactone carries a firm contraindication in pregnancy.

This is why women of childbearing age who are prescribed spironolactone are generally advised to use reliable contraception. The risk is specific to male fetal development; there is no evidence of comparable harm to female fetuses, consistent with the drug’s androgen-blocking mechanism being the culprit. If a pregnancy is discovered while taking spironolactone, the drug is stopped immediately, though case reports of accidental mid-pregnancy exposure have not always resulted in detectable harm.

Progesterone Receptor Activity and Meningioma Concerns

Beyond androgens and mineralocorticoids, spironolactone has some affinity for progesterone receptors. This has raised a question about whether long-term use could promote the growth of meningiomas, brain tumors known to be stimulated by progesterone receptor activation. The concern was heightened after another progesterone-like drug, cyproterone acetate, was linked to increased meningioma risk in Europe. However, a population-based cohort study found that despite its progesterone receptor affinity, spironolactone was not associated with meningioma development.¹⁹ That finding provides reassurance, though it does illustrate how broadly spironolactone interacts with hormone receptors and why each new interaction raises questions about potential downstream consequences.

Spironolactone also has weak estrogenic activity, which contributes to some of its feminizing side effects in men. The menstrual irregularities many women experience on spironolactone, including spotting between periods and changes in cycle length, are likely a combined result of its anti-androgen, progestogenic, and mild estrogenic properties acting together. These effects are generally dose-dependent and reversible after stopping the medication, but they underscore the point that spironolactone is not a precision tool. It is a drug that talks to multiple hormone systems at once, and its clinical usefulness depends on which of those conversations you want it to have.